Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatment
AssigneeOse Immunotherapeutics
InventorsNicolas Poirier, Caroline Mary
Life of this patent
Estimating the term…
Abstract
The description concerns humanized antibodies directed against the extracellular domain of the alpha chain of the receptor for interleukin-7 (IL-7), especially against the receptor for human IL-7 expressed on human cells (also designated human IL-7Ralpha or IL-7Ra or CD127) and which do not interfere with the IL-7 or TSLP signaling pathways. The antibodies described do not have an antagonistic effect on the IL-7 receptor, but may still present cytotoxic activity against CD127 positive cells. In a particular embodiment, the antibody does not have an agonist effect on the IL-7 receptor.
Claims28
An antibody or an antigen-binding fragment thereof, which comprises the following CDRs:
- VH-CDR1 the amino acid sequence of which is Effi3-VH3-CDR1 of SEQ ID No14;
- VH-CDR2 the amino acid sequence of which is Effi3-VH3-CDR2 of SEQ ID No16;
- VH-CDR3 the amino acid sequence of which is Effi3-VH3-CDR3 sequence of SEQ ID No18;
- VL-CDR2 the amino acid sequence of which is Effi3-VL3-CDR2 of SEQ ID No22;
- VL-CDR3 the amino acid sequence of which is Effi3-VL3-CDR3 of SEQ ID No24;
- and
- VL-CDR1 the amino acid sequence of which is Effi3-VL3-CDR1 of SEQ ID No20 or the amino acid sequence of which is Effi3-VL4-CDR1 of SEQ ID No26,
- wherein the antibody or the antigen-binding fragment thereof binds specifically to the extracellular domain of human CD127 and is not an antagonist of CD127.
Dependencies are inferred from the claim text.